Page last updated: 2024-12-04

4-methylumbelliferyl acetate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

4-methylumbelliferyl acetate : An acetate ester consiting of umbelliferone carrying a 7-O-acetyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID366
CHEMBL ID12019
CHEBI ID17763
SCHEMBL ID335474
MeSH IDM0100321

Synonyms (84)

Synonym
einecs 220-386-6
unii-zd294d576m
nsc 44763
nsc 1059
zd294d576m ,
nsc 31658
7-acetoxy-4-methylchromen-2-one
7-(acetyloxy)-4-methyl-2-benzopyrone
7-(acetyloxy)-4-methyl-2h-1-benzopyran-2-one
beta-methylumbelliferyl acetate
CHEBI:17763 ,
4-methyl-2-oxo-2h-chromen-7-yl acetate
7-acetoxy-4-methylcoumarin
4-methyl-7-acetyloxy coumarin
acetic acid 4-methyl-2-oxo-2h-chromen-7-yl ester
MLS000554751 ,
smr000146868
nsc-44763
nsc44763
nsc-31658
nsc31658
IFLAB2_000119
IFLAB1_001442
NCI60_002720
EU-0039270
nsc688806
4-methyl-umbelliferone, acetate
(4-methyl-2-oxo-chromen-7-yl) acetate
MEGXP0_001897
nsc1059
4-methylumbelliferyl acetate
2h-1-benzopyran-2-one, 7-(acetyloxy)-4-methyl-
2747-05-9
nsc-1059
C03837
4-methylumbelliferyl acetate, esterase substrate
nsc-688806
IDI1_019145
NCI60_000142
M-5490
STK395120
AC-11030
AKOS000323400
4-methyl umbelliferone acetate
CHEMBL12019
HMS1416B12
FT-0653132
(4-methyl-2-oxochromen-7-yl) acetate
NCGC00246518-01
7-acetyl-4-methylcoumarin
A819082
HMS2290M10
F0415-0023
FT-0621336
mu-ac
CCG-214462
AB00448415-08
SCHEMBL335474
.beta.-methylumbelliferyl acetate
4-methyl-2-oxo-2h-chromen-7-yl acetate #
J-100194
acetic acid (4-methyl-2-oxo-1-benzopyran-7-yl) ester
cid_366
bdbm33456
acetic acid (2-keto-4-methyl-chromen-7-yl) ester
(4-methyl-2-oxidanylidene-chromen-7-yl) ethanoate
mfcd00006865
DTXSID70181895
SR-01000443138-1
sr-01000443138
7-acetoxy-4-methyl-2h-1-benzopyran-2-one
BCP21289
Q27102589
AS-12521
AM9987
hymecromone acetate
hymecromone acetate; 4-methylumbelliferyl acetate
7-acetoxy-4-methyl coumarin
4-methyl-2-oxo-2h-chromen-7-ylacetate
coumarin, 7-hydroxy-4-methyl-, acetate
7-hydroxy-4-methylcoumarin acetate
7-(acetyloxy)-4-methylcoumarin
.beta.-methylumbelliferone acetate
acetyl hymetochrome

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Since P-450 catalyzed oxidation of benzene is crucial to its toxic effects, the action of DAMC and related analogues were considered promising in preventing the genotoxicity due to benzene."( Chemoprevention of benzene-induced bone marrow and pulmonary genotoxicity.
Adhikari, JS; Bose, M; Dwarakanath, BS; Jain, SC; Kohli, E; Malik, S; Olsen, CE; Parmar, VS; Raj, HG; Rohil, V; Tyagi, YK, 2001
)
0.31
" The less and more toxic ILs found in this study were emim [Ms] and tbph [Ms], respectively."( Automated carboxylesterase assay for the evaluation of ionic liquids' human toxicity.
Carvalho, JP; Cunha, E; Pinto, PC; Saraiva, ML, 2013
)
0.39
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
acetate esterAny carboxylic ester where the carboxylic acid component is acetic acid.
coumarins
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (17)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency31.62280.177814.390939.8107AID2147
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID485281
thioredoxin reductaseRattus norvegicus (Norway rat)Potency25.11890.100020.879379.4328AID588456
ClpPBacillus subtilisPotency25.11891.995322.673039.8107AID651965
TDP1 proteinHomo sapiens (human)Potency5.17350.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency3.16230.011212.4002100.0000AID1030
glucocerebrosidaseHomo sapiens (human)Potency19.95260.01268.156944.6684AID2101
alpha-galactosidaseHomo sapiens (human)Potency35.48134.466818.391635.4813AID1467; AID2107
lysosomal alpha-glucosidase preproproteinHomo sapiens (human)Potency36.92440.036619.637650.1187AID1466; AID2112; AID2242
importin subunit beta-1 isoform 1Homo sapiens (human)Potency73.24415.804836.130665.1308AID540253; AID540263
snurportin-1Homo sapiens (human)Potency73.24415.804836.130665.1308AID540253; AID540263
GTP-binding nuclear protein Ran isoform 1Homo sapiens (human)Potency20.59625.804816.996225.9290AID540253
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency35.48133.548118.039535.4813AID1466
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)Potency35.48133.548118.039535.4813AID1466
Inositol monophosphatase 1Rattus norvegicus (Norway rat)Potency11.22021.000010.475628.1838AID1457
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Coagulation factor XIIHomo sapiens (human)IC50 (µMol)50.00000.01043.889010.9666AID728
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (29)

Processvia Protein(s)Taxonomy
plasma kallikrein-kinin cascadeCoagulation factor XIIHomo sapiens (human)
Factor XII activationCoagulation factor XIIHomo sapiens (human)
blood coagulation, intrinsic pathwayCoagulation factor XIIHomo sapiens (human)
positive regulation of plasminogen activationCoagulation factor XIIHomo sapiens (human)
protein processingCoagulation factor XIIHomo sapiens (human)
protein autoprocessingCoagulation factor XIIHomo sapiens (human)
positive regulation of blood coagulationCoagulation factor XIIHomo sapiens (human)
zymogen activationCoagulation factor XIIHomo sapiens (human)
fibrinolysisCoagulation factor XIIHomo sapiens (human)
innate immune responseCoagulation factor XIIHomo sapiens (human)
response to misfolded proteinCoagulation factor XIIHomo sapiens (human)
positive regulation of fibrinolysisCoagulation factor XIIHomo sapiens (human)
blood coagulationCoagulation factor XIIHomo sapiens (human)
cholesterol biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
response to toxic substanceLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol effluxLiver carboxylesterase 1Homo sapiens (human)
negative regulation of cholesterol storageLiver carboxylesterase 1Homo sapiens (human)
epithelial cell differentiationLiver carboxylesterase 1Homo sapiens (human)
cholesterol homeostasisLiver carboxylesterase 1Homo sapiens (human)
reverse cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
medium-chain fatty acid metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid biosynthetic processLiver carboxylesterase 1Homo sapiens (human)
cellular response to cholesterolLiver carboxylesterase 1Homo sapiens (human)
cellular response to low-density lipoprotein particle stimulusLiver carboxylesterase 1Homo sapiens (human)
cholesterol ester hydrolysis involved in cholesterol transportLiver carboxylesterase 1Homo sapiens (human)
positive regulation of cholesterol metabolic processLiver carboxylesterase 1Homo sapiens (human)
regulation of bile acid secretionLiver carboxylesterase 1Homo sapiens (human)
lipid catabolic processLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
serine-type endopeptidase activityCoagulation factor XIIHomo sapiens (human)
calcium ion bindingCoagulation factor XIIHomo sapiens (human)
protein bindingCoagulation factor XIIHomo sapiens (human)
misfolded protein bindingCoagulation factor XIIHomo sapiens (human)
sterol esterase activityLiver carboxylesterase 1Homo sapiens (human)
methylumbelliferyl-acetate deacetylase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylesterase activityLiver carboxylesterase 1Homo sapiens (human)
carboxylic ester hydrolase activityLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (11)

Processvia Protein(s)Taxonomy
extracellular regionCoagulation factor XIIHomo sapiens (human)
extracellular spaceCoagulation factor XIIHomo sapiens (human)
plasma membraneCoagulation factor XIIHomo sapiens (human)
collagen-containing extracellular matrixCoagulation factor XIIHomo sapiens (human)
extracellular exosomeCoagulation factor XIIHomo sapiens (human)
extracellular spaceCoagulation factor XIIHomo sapiens (human)
rough endoplasmic reticulumCoagulation factor XIIHomo sapiens (human)
cytoplasmLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulum lumenLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
cytosolLiver carboxylesterase 1Homo sapiens (human)
lipid dropletLiver carboxylesterase 1Homo sapiens (human)
endoplasmic reticulumLiver carboxylesterase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (30)

Assay IDTitleYearJournalArticle
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID290105Inhibition of liver microsomal EROD at 25 uM2007European journal of medicinal chemistry, Apr, Volume: 42, Issue:4
Specificities of acetoxy derivatives of coumarins, biscoumarins, chromones, flavones, isoflavones and xanthones for acetoxy drug: protein transacetylase.
AID34983Compound was tested for percent inhibition at 10 e-4 M against rat lens aldose reductase1986Journal of medicinal chemistry, Jun, Volume: 29, Issue:6
Synthesis and rat lens aldose reductase inhibitory activity of some benzopyran-2-ones.
AID393123Increase in NO levels in citreated human platelet rich plasma assessed as enhancement of dichloro fluorescein fluorescence by flow cytometry2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Specificities of calreticulin transacetylase to acetoxy derivatives of 3-alkyl-4-methylcoumarins: effect on the activation of nitric oxide synthase.
AID393122Inhibition of rat liver microsomal CRTAase catalyzed activation of NADPH cytochrome C reductase2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Specificities of calreticulin transacetylase to acetoxy derivatives of 3-alkyl-4-methylcoumarins: effect on the activation of nitric oxide synthase.
AID456232Activity at human recombinant CES1 expressed in baculovirus-infected Spodoptera frugiperda Sf21 cells assessed as substrate hydrolysis by fluorescence assay2010Bioorganic & medicinal chemistry, Jan-01, Volume: 18, Issue:1
In silico prediction of human carboxylesterase-1 (hCES1) metabolism combining docking analyses and MD simulations.
AID1138894Antiasthamic activity in Wistar rat tracheal ring assessed as reversal of carbachol-induced contraction2014European journal of medicinal chemistry, Apr-22, Volume: 77Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs.
AID1138893Antiasthamic activity in Wistar rat tracheal ring assessed as reversal of carbachol-induced contraction at 0.1 to 500 uM relative to control2014European journal of medicinal chemistry, Apr-22, Volume: 77Semisynthesis, ex vivo evaluation, and SAR studies of coumarin derivatives as potential antiasthmatic drugs.
AID290106Inhibition of micronuclei formation in benzene-induced in Wistar Albino rat bone marrow cells at 300 mg/ kg, ip after 1 hr2007European journal of medicinal chemistry, Apr, Volume: 42, Issue:4
Specificities of acetoxy derivatives of coumarins, biscoumarins, chromones, flavones, isoflavones and xanthones for acetoxy drug: protein transacetylase.
AID290103Effect on TAase activity assessed as inhibition of GST in liver microsome at 50 uM2007European journal of medicinal chemistry, Apr, Volume: 42, Issue:4
Specificities of acetoxy derivatives of coumarins, biscoumarins, chromones, flavones, isoflavones and xanthones for acetoxy drug: protein transacetylase.
AID393121Inhibition of rat liver microsomal CRTAase-mediated inhibition of cytosolic glutathione S-transferase activity2009Bioorganic & medicinal chemistry, Feb-15, Volume: 17, Issue:4
Specificities of calreticulin transacetylase to acetoxy derivatives of 3-alkyl-4-methylcoumarins: effect on the activation of nitric oxide synthase.
AID290104Effect on TAase activity assessed as activation of liver microsomal NADPH cytochrome P450 at 5 uM2007European journal of medicinal chemistry, Apr, Volume: 42, Issue:4
Specificities of acetoxy derivatives of coumarins, biscoumarins, chromones, flavones, isoflavones and xanthones for acetoxy drug: protein transacetylase.
AID412236Lipophilicity, log P of the compound2009Bioorganic & medicinal chemistry, Jan-01, Volume: 17, Issue:1
Comparison of benzil and trifluoromethyl ketone (TFK)-mediated carboxylesterase inhibition using classical and 3D-quantitative structure-activity relationship analysis.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (11.11)18.7374
1990's2 (5.56)18.2507
2000's11 (30.56)29.6817
2010's14 (38.89)24.3611
2020's5 (13.89)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.17 (24.57)
Research Supply Index3.61 (2.92)
Research Growth Index5.20 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other36 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]